Topical corticosteroids: potency, vehicles and safety
How skin steroids are ranked from mild to very potent, how the base changes their effect, and how to avoid skin thinning and systemic effects.
Topical corticosteroids are the main anti-inflammatory treatment for eczema, psoriasis and many other skin diseases. They differ widely in strength. The right choice depends on the disease, the body site, the patient's age and the length of treatment. The general rule is to use the weakest steroid that controls the problem, for the shortest time needed.
Potency groups, by example
A common four-group scale ranks steroids by strength. Each step up controls inflammation faster but carries more local and systemic risk. The same molecule can appear in different groups depending on its ester and formulation.
- Mild: hydrocortisone, hydrocortisone acetate
- Moderate: clobetasone butyrate, triamcinolone acetonide, hydrocortisone butyrate
- Potent: betamethasone valerate, mometasone furoate
- Very potent: clobetasol propionate
Vehicles
The base, or vehicle, changes how much steroid passes into the skin and where the product is practical to use.
- Ointments: greasy and occlusive, good for dry, thick, non-hairy skin; occlusion increases penetration but can cause folliculitis
- Creams and lotions: general-purpose and the most widely used
- Gels and solutions: for hairy areas such as the scalp; they dry lesions but can sting inflamed skin
Adverse effects
Most adverse effects come from using a steroid that is too strong, for too long, or on the wrong site. Systemic effects are rare with sensible use.
- Local: skin thinning (atrophy), striae, telangiectasia, purpura, local hair growth, lighter skin
- Facial: perioral (periorificial) dermatitis and steroid rosacea
- Infection: can worsen or mask impetigo, herpes and tinea (tinea incognito)
- Around the eyes: long, heavy use can contribute to glaucoma or cataract
- Systemic: HPA axis suppression, Cushing syndrome and high blood sugar, mainly with very potent steroids over large areas or under occlusion
Sites at risk
Absorption is highest where the skin is thin or folded and lowest on the palms and soles. Very potent steroids are not used on the face, groin or armpits, and are not placed under occlusive dressings unless a specialist directs it. Thick skin on palms and soles may need a stronger steroid to work.
Children
Children have more skin surface for their body mass, so they absorb proportionally more steroid. This raises the risk of HPA axis suppression, Cushing syndrome and effects on growth. Very potent steroids such as clobetasol are not recommended under 12 years. Children also need smaller amounts per application than adults.
Pregnancy and stopping treatment
Mild and moderate steroids can be used in pregnancy; potent and very potent ones over large areas or under occlusion need caution because some is absorbed. Prolonged use of potent steroids, especially on the face, can be followed by flares and withdrawal symptoms when they are stopped, so strong steroids are reduced in a planned way. Emollients are continued alongside.
Test yourself
Think of the answer, then tap the question to see it.
Which potency group does clobetasol propionate belong to, and which does hydrocortisone belong to?
Clobetasol propionate is very potent; hydrocortisone is mild.
Why do the eyelids, face and skin folds need weaker steroids?
Their thin skin absorbs much more steroid, so atrophy and other side effects appear faster.
Why are children at higher risk of systemic effects from topical steroids?
They have a larger skin surface for their body mass, so they absorb proportionally more steroid.
Which test can show HPA axis suppression from a very potent topical steroid?
An ACTH stimulation test (with tetracosactide); morning cortisol or urinary free cortisol can also be used.
Example drugs
Connections
Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.
Sources: Topical steroid (DermNet, 2016); DailyMed - CLOBETASOL PROPIONATE cream (DailyMed (U.S. National Library of Medicine), 2026); Steroids - NHS (NHS, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.